BibTex RIS Cite

Preoperative Predictive Value of Neuthrophil/Lymphocyte Ratios in Testicular Tumors

Year 2013, Volume: 20 Issue: 3, 243 - 245, 01.06.2013

Abstract

Objective: It has been demonstrated that neuthrophil/lymphocyte ratio is an independent prognostic factor in many cancers such as bladder tumor and renal tumor. Whether any differences neuthrophil/lymphocyte ratio regarding the pathological stage of testicular tumor was assessed in this study. Meterial and Methods: 21 patients underwent orchiectomy for testicular mass in our clinic were included to the study. Neuthrophil/lymphocyte ratios of both groups were obtained from preoperative blood count. Patients were divided into two groups as Group 1 and 2, which contain stage 1 and ≥stage 2 diseases, respectively. Neuthrophil/lymphocyte ratios of both groups were compared statistically using the Mann Whitney U test. Results: Pathologic examination revealed pure seminoma in 10 patients, mixt germ cell tumor in 6 patients, lymphoma in 1 patient, adenomatoid tumor in 1 patient, fibroma in 1 patient, small round cell ca in 1 patient and leydig cell tumor in 1 patient. Pathologic examination revealed benign pathology in 3 patients. There were 9 patients in each group. The mean neuthrophil/lymphocyte ratios for group 1 and 2 were 1.99 (SD: 0.779) and 2.74 (SD: 1.484), respectively. There was no statistically significant difference between both groups regarding the neuthrophil/lymphocyte ratio (p=0.270). Conclusion: Neuthrophil/lymphocyte ratio could not predict the pathological stage of testicular tumor preoperatively. Larger series and long-term follow-ups are needed to determine of prognostic effect of neuthrophil/lymphocyte ratio on testicular tumor. Key words: Testis; Seminoma; NLR; Prognosis.

References

  • Ferlay J, Shin H.R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 IntJ Cancer 2010;127:2893-917.
  • Okutur K, Demir G. Testis tümörlerinin sistemik kemoterapisine bağlı erken ve geç yan etkiler. Üroonkoloji Bülteni 2008;3:10—14.
  • Hahn NM, Sweeney CJ. Germ cell tumors: an update of recent data and review of active protocols in stage | and metastatic disease. Urol Oncol 2005;23:293-302.
  • Diamantopoulos N, Kortsaris A. Testicular germ cell tumors. J BUON 201 O;15:421—34.
  • Van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIA. Chest 2000;117:374—9.
  • Leman ES, Gonzalgo ML. Prognostic features and markers for testicular cancer management. Indian J Urol 2010;26:76-81.
  • Yamanaka T, Matsumoto S, Teramukai S, lshiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215—20.
  • Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for lL—2 immunotherapy. J lmmunother 2003;26:394—402.
  • Yalçınkaya U, Çalışır B, Uğraşı N, Filiz G, Erol O. Testis tümörleri: 30 yıllık arşiv tarama sonuçları. Türk Patoloji Dergisi 2008;24:100—6.
  • Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz—Ares L,
  • Arranz JA, Guma J et al. Clinical pattern and therapeutic
  • results achieved n 1490 patients with germ—cell tumors of
  • the testis: the experience of the Spanish Germ-Cell Cancer
  • Group (GG). Eur Urol 2002;42:553-63.
  • Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: An overview. Int J Cancer 2005;116:331—9.
  • Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277—308.
  • von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377—427.
  • Trigo JM, Tabernero JM, Paz—Ares L, Garcia-Llano JL, Mora
  • J, Lianes P et al. Tumor markers at the time of recurrence in
  • patients with germ cell tumors. Cancer 2000;88:162—8.
  • Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al. 18F—FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.
  • Gibson PH, Cuthbertson BH, Croal BL, Rae D, El—Shafei H, Gibson G et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new—onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010;105:186—91.
  • Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K et al. Pretreatment neutrophil counts as an independent prognostic factor in advanced non—small cell lung canceran analysis of Japan multinational trial organization LCOO-O3. Eur J Cancer 2009;45:1950—8.
  • Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J et al. Prognostic factors for survival in advanced non—small—cell lung cancerzunivariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer
  • Working Party. J Clin Oncol 1995;13:1221—30.
  • Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation—based prognostic score in patients with metastatic renal cancer. Cancer 2007;109:205- 12.
  • Symbas NP, Townsend MF, El—Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000;86:203-7.
  • Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J 2010;123:3438-43.

Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri

Year 2013, Volume: 20 Issue: 3, 243 - 245, 01.06.2013

Abstract

Amaç: Nötrofil/Lenfosit oranının mesane kanseri ve böbrek tümörü gibi birçok kanserde bağımsız bir prognostik faktör olduğu gösterilmiştir. Bu çalışmada testis tümörlerinin farklı evrelerinde, Nötrofil/Lenfosit oranında herhangi bir değişim olup olmadığını tespit etmeyi amaçladık. Gereç ve Yöntemler: Kliniğimizde testis tümörü şüphesi ile orşiektomi yapılmış 21 hastanın patoloji sonuçları geriye dönük olarak incelendi. Tüm hastaların operasyon öncesi kan değerlerinden Nötrofil/Lenfosit oranları tespit edildi. Evre 1 hastalar grup 1 ve evre 2 ve üzeri hastalar grup 2 olarak sınıflandırıldı. Her grupta 9' ar hasta mevcuttu. Her iki grubun da Nötrofil/Lenfosit oranları Mann-Whitney U testi kullanılarak istatistiksel olarak karşılaştırıldı. Bulgular: Patolojik inceleme sonucunda 10 hastada saf seminom, 6 hastada miks germ hücreli tümör, 1 hastada lenfoma, 1 hastada adenomatoid tümör, 1 hastada fibroma, 1 hastada small round cell ve 1 hastada ise leydig hücreli tümör tespit edildi. Her bir grupta 9 hasta bulunmaktaydı. Grup 1 ve 2 ‘nin ortalama Nötrofil/Lenfosit oranları sırasıyla, 1.99 (SD: 0.779) ve 2.74 (SD: 1.484) idi. Nötrofil/Lenfosit oranları açısından bakıldığında bu iki grup arasında anlamlı bir fark olmadığı saptandı (p=0.270). Sonuç: Nötrofil/Lenfosit oranları testis tümörünün evresini operasyon öncesinden tahmin edememektedir. Ancak Nötrofil/Lenfosit oranlarının testis tümöründeki prognostik değerinin ortaya çıkarılması için daha geniş serilere ve daha uzun hasta takip sürelerinde ihtiyaç vardır. Anahtar kelimeler: Testis; Seminom; NLR; Prognoz.

References

  • Ferlay J, Shin H.R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 IntJ Cancer 2010;127:2893-917.
  • Okutur K, Demir G. Testis tümörlerinin sistemik kemoterapisine bağlı erken ve geç yan etkiler. Üroonkoloji Bülteni 2008;3:10—14.
  • Hahn NM, Sweeney CJ. Germ cell tumors: an update of recent data and review of active protocols in stage | and metastatic disease. Urol Oncol 2005;23:293-302.
  • Diamantopoulos N, Kortsaris A. Testicular germ cell tumors. J BUON 201 O;15:421—34.
  • Van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIA. Chest 2000;117:374—9.
  • Leman ES, Gonzalgo ML. Prognostic features and markers for testicular cancer management. Indian J Urol 2010;26:76-81.
  • Yamanaka T, Matsumoto S, Teramukai S, lshiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215—20.
  • Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for lL—2 immunotherapy. J lmmunother 2003;26:394—402.
  • Yalçınkaya U, Çalışır B, Uğraşı N, Filiz G, Erol O. Testis tümörleri: 30 yıllık arşiv tarama sonuçları. Türk Patoloji Dergisi 2008;24:100—6.
  • Germa-Lluch JR, Garcia del Muro X, Maroto P, Paz—Ares L,
  • Arranz JA, Guma J et al. Clinical pattern and therapeutic
  • results achieved n 1490 patients with germ—cell tumors of
  • the testis: the experience of the Spanish Germ-Cell Cancer
  • Group (GG). Eur Urol 2002;42:553-63.
  • Garner MJ, Turner MC, Ghadirian P, Krewski D. Epidemiology of testicular cancer: An overview. Int J Cancer 2005;116:331—9.
  • Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277—308.
  • von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377—427.
  • Trigo JM, Tabernero JM, Paz—Ares L, Garcia-Llano JL, Mora
  • J, Lianes P et al. Tumor markers at the time of recurrence in
  • patients with germ cell tumors. Cancer 2000;88:162—8.
  • Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al. 18F—FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.
  • Gibson PH, Cuthbertson BH, Croal BL, Rae D, El—Shafei H, Gibson G et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new—onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2010;105:186—91.
  • Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K et al. Pretreatment neutrophil counts as an independent prognostic factor in advanced non—small cell lung canceran analysis of Japan multinational trial organization LCOO-O3. Eur J Cancer 2009;45:1950—8.
  • Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J et al. Prognostic factors for survival in advanced non—small—cell lung cancerzunivariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer
  • Working Party. J Clin Oncol 1995;13:1221—30.
  • Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation—based prognostic score in patients with metastatic renal cancer. Cancer 2007;109:205- 12.
  • Symbas NP, Townsend MF, El—Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000;86:203-7.
  • Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J 2010;123:3438-43.
There are 28 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Mehmet Erol Yıldırım This is me

Hüseyin Badem This is me

Ömer Faruk Karataş This is me

Ersin Çimentepe This is me

Publication Date June 1, 2013
Published in Issue Year 2013 Volume: 20 Issue: 3

Cite

APA Yıldırım, M. E., Badem, H., Karataş, Ö. F., Çimentepe, E. (2013). Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. Journal of Turgut Ozal Medical Center, 20(3), 243-245.
AMA Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E. Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. J Turgut Ozal Med Cent. June 2013;20(3):243-245.
Chicago Yıldırım, Mehmet Erol, Hüseyin Badem, Ömer Faruk Karataş, and Ersin Çimentepe. “Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri”. Journal of Turgut Ozal Medical Center 20, no. 3 (June 2013): 243-45.
EndNote Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E (June 1, 2013) Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. Journal of Turgut Ozal Medical Center 20 3 243–245.
IEEE M. E. Yıldırım, H. Badem, Ö. F. Karataş, and E. Çimentepe, “Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri”, J Turgut Ozal Med Cent, vol. 20, no. 3, pp. 243–245, 2013.
ISNAD Yıldırım, Mehmet Erol et al. “Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri”. Journal of Turgut Ozal Medical Center 20/3 (June 2013), 243-245.
JAMA Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E. Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. J Turgut Ozal Med Cent. 2013;20:243–245.
MLA Yıldırım, Mehmet Erol et al. “Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri”. Journal of Turgut Ozal Medical Center, vol. 20, no. 3, 2013, pp. 243-5.
Vancouver Yıldırım ME, Badem H, Karataş ÖF, Çimentepe E. Preoperatif Nötrofil/Lenfosit Oranının Testis Tümörlerinin Evresinin Tespitindeki Prediktif Değeri. J Turgut Ozal Med Cent. 2013;20(3):243-5.